Deborah Mukherji· @dmukherji · X·· 2 days agoScore70
Body · original
More on ctDNA as a dynamic biomarker in prostate cancer at #ESMO26 @AzadOncology @OncoAlert
In TALAPRO-3, ctDNA tumour fraction clearance at week 5 was higher with talazoparib + enzalutamide (82% vs 68%) and associated with longer rPFS.
215 views · 4 likes · 4 reposts · 0 replies
Conference abstracts
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.orgSource: Deborah Mukherji · x.com